Endometrial inadequacy after treatment with human menopausal gonadotropin/human chorionic gonadotropin.
The incidence of abnormal endometrial histology in patients undergoing human menopausal gonadotropin/human chorionic gonadotropin (hMG/hCG) treatment during cycles of in vitro fertilization (IVF) or gamete intrafallopian transfer has been reported to be 52% to 91%. The incidence of endometrial inadequacy, as judged by a single late luteal endometrial biopsy, has not been studied in hMG/hCG non-IVF cycles. In the current study, 30 patients (30 cycles) undergoing hMG/hCG treatment were evaluated by an endometrial biopsy. The incidence of endometrial inadequacy was found to be 27%. No preovulatory predictors for endometrial inadequacy could be identified. Therefore, luteal support for patients undergoing non-IVF hMG/hCG cycles should be considered.
Reshef
E
E
Department of Obstetrics and Gynecology, University of Louisville School of Medicine, Kentucky.
Segars
J H
JH
Hill
G A
GA
Pridham
D D
DD
Yussman
M A
MA
Wentz
A C
AC
D000328:Adult; D001706:Biopsy; D006063:Chorionic Gonadotropin / Q000009:adverse effects* / Q000627:therapeutic use; D004717:Endometrium / Q000187:drug effects / Q000473:pathology*; D004958:Estradiol / Q000378:metabolism; D005260:Female; D006801:Humans; D008183:Luteal Phase; D008596:Menotropins / Q000009:adverse effects* / Q000627:therapeutic use; D008597:Menstrual Cycle / Q000187:drug effects; D006080:Ovarian Follicle / Q000378:metabolism; D012016:Reference Values
D006063:Chorionic Gonadotropin; D004958:Estradiol; D008596:Menotropins